Stock Insiders is podcast series focused investing hosted by TV presenter and news journalist Christina Morrissy. 

In this episode Christina chats to Dr Liz Dallimore, CEO & managing director at Argenica Therapeutics (ASX:AGN).

Argenica develop and seek to commercialise a “best in class” neuroprotective cationic arginine-rich peptide therapy to improve outcomes in stroke patients. It has developed a neuroprotective drug that can be administered in the field by paramedics, and used in conjunction with endovascular therapy (thrombolysis/thrombectomy) to improve neuroprotective outcomes, and importantly increase the number of patients amenable to thrombolysis and thrombectomy.

A safety report released on March 6 has given Argenica the confidence to progress to the Phase 2 clinical trial in stroke patients later this year.

The company recently secured non-dilutive cash funding from the Stan Perron Charitable Foundation (SPCF) via the Perron Institute for Neurological and Translational Sciences to progress preclinical studies into the efficacy of its ARG-007 drug in neonatal Hypoxic Ischaemic Encephalopathy (HIE).

On mobile? Click here to listen with Apple podcasts, here for Spotify.

Like to tune in through another app? Just search for Stock Insiders with Christina Morrissy and subscribe!

Read MoreBiotech

Featured Companies

You might be interested in